Array BioPharma and AstraZeneca plan to add two additional randomized Phase II trials for AZD6244 (ARRY-886). The trials, which will begin 2H08, will study AZD6244 in combination with a cytotoxic chemotherapeutic agent; one trial will be in melanoma patients and the other in non-small cell lung cancer patients. These plans are based on AZD6244’s activity as a single agent in previous monotherapy Phase II trials and preclinical data.     “We believe that AZD6244 holds promise for cancer patie...